These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 25245515)
1. Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study. McConnell HL; Perris ET; Lowry C; Lodise T; Patel N Infect Dis Ther; 2014 Dec; 3(2):225-33. PubMed ID: 25245515 [TBL] [Abstract][Full Text] [Related]
2. Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: A systematic review and meta-analysis. Samura M; Takada K; Hirose N; Kurata T; Nagumo F; Koshioka S; Ishii J; Uchida M; Inoue J; Enoki Y; Taguchi K; Tanikawa K; Matsumoto K Br J Clin Pharmacol; 2022 May; 88(5):1985-1998. PubMed ID: 34902879 [TBL] [Abstract][Full Text] [Related]
3. Musculoskeletal toxicities in patients receiving concomitant statin and daptomycin therapy. Kido K; Oyen AA; Beckmann MA; Brouse SD Am J Health Syst Pharm; 2019 Feb; 76(4):206-210. PubMed ID: 30689699 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of impact of statin use on development of CPK elevation during daptomycin therapy. Berg ML; Estes LL; Dierkhising RA; Curran B; Enzler MJ Ann Pharmacother; 2014 Mar; 48(3):320-7. PubMed ID: 24321853 [TBL] [Abstract][Full Text] [Related]
5. A Retrospective Multisite Case-Control Series of Concomitant Use of Daptomycin and Statins and the Effect on Creatine Phosphokinase. Lehman B; Neuner EA; Heh V; Isada C Open Forum Infect Dis; 2019 Nov; 6(11):ofz444. PubMed ID: 31723571 [TBL] [Abstract][Full Text] [Related]
6. Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors. Bland CM; Bookstaver PB; Lu ZK; Dunn BL; Rumley KF; Antimicrob Agents Chemother; 2014 Oct; 58(10):5726-31. PubMed ID: 25022580 [TBL] [Abstract][Full Text] [Related]
7. Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods. Imai S; Kashiwagi H; Sato Y; Miyai T; Sugawara M; Takekuma Y Br J Clin Pharmacol; 2022 Mar; 88(3):1211-1222. PubMed ID: 34436795 [TBL] [Abstract][Full Text] [Related]
8. Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy. Dare RK; Tewell C; Harris B; Wright PW; Van Driest SL; Farber-Eger E; Nelson GE; Talbot TR Clin Infect Dis; 2018 Oct; 67(9):1356-1363. PubMed ID: 29668884 [TBL] [Abstract][Full Text] [Related]
9. Identification of Risk Factors for Daptomycin-Associated Creatine Phosphokinase Elevation and Development of a Risk Prediction Model for Incidence Probability. Samura M; Hirose N; Kurata T; Takada K; Nagumo F; Koshioka S; Ishii J; Uchida M; Inoue J; Enoki Y; Taguchi K; Higashita R; Kunika N; Tanikawa K; Matsumoto K Open Forum Infect Dis; 2021 Dec; 8(12):ofab568. PubMed ID: 34888403 [TBL] [Abstract][Full Text] [Related]
10. Observational retrospective single-centre study in Japan to assess the clinical significance of serum daptomycin levels in creatinine phosphokinase elevation. Ando M; Nishioka H; Nakasako S; Kuramoto E; Ikemura M; Kamei H; Sono Y; Sugioka N; Fukushima S; Hashida T J Clin Pharm Ther; 2020 Apr; 45(2):290-297. PubMed ID: 31696963 [TBL] [Abstract][Full Text] [Related]
11. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Bhavnani SM; Rubino CM; Ambrose PG; Drusano GL Clin Infect Dis; 2010 Jun; 50(12):1568-74. PubMed ID: 20462352 [TBL] [Abstract][Full Text] [Related]
13. Patient Case Report Daptomycin Holiday-A Daptomycin Dosing Strategy for Asymptomatic Increases in Creatine Phosphokinase Levels. Koh L; Shah PJ; Aly S J Pharm Pract; 2022 Feb; 35(1):148-151. PubMed ID: 32924753 [TBL] [Abstract][Full Text] [Related]
14. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Golightly LK; Barber GR; Barron MA; Page RL Drug Metabol Drug Interact; 2013; 28(1):49-58. PubMed ID: 23314530 [TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Bookstaver PB; Bland CM; Qureshi ZP; Faulkner-Fennell CM; Sheldon MA; Caulder CR; Hartis C; Pharmacotherapy; 2013 Dec; 33(12):1322-30. PubMed ID: 23712701 [TBL] [Abstract][Full Text] [Related]
16. Effects of statin use on serum creatinine phosphokinase levels in normal thyroid function. Ha J; Lee J; Yu J; Park H; Shinn J; Lee SH; Cho JH; Kim HS Korean J Intern Med; 2024 Jul; 39(4):650-658. PubMed ID: 38910508 [TBL] [Abstract][Full Text] [Related]
17. Statin-induced necrotizing autoimmune myopathy: An uncommon complication of a commonly used medication. Saleh Y; Herzallah K; Hassanein M; Chang HT J Saudi Heart Assoc; 2019 Oct; 31(4):269-272. PubMed ID: 31516306 [TBL] [Abstract][Full Text] [Related]
18. Statin-Induced Autoimmune Myopathy. Nemati M; Srai M; Rudrangi R Cureus; 2021 Feb; 13(2):e13576. PubMed ID: 33815984 [TBL] [Abstract][Full Text] [Related]
19. A safety and clinical efficacy analysis of PCSK9 monoclonal antibodies in patients with markedly elevated creatine phosphokinase levels. Volis I; Hislop E; Saliba W; Zafrir B Am J Blood Res; 2021; 11(4):399-404. PubMed ID: 34540348 [TBL] [Abstract][Full Text] [Related]
20. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Figueroa DA; Mangini E; Amodio-Groton M; Vardianos B; Melchert A; Fana C; Wehbeh W; Urban CM; Segal-Maurer S Clin Infect Dis; 2009 Jul; 49(2):177-80. PubMed ID: 19500039 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]